Our service includes a comprehensive consult to help identify gaps and opportunities, a complete report that includes a project plan with timelines and milestones, a cost analysis, and a schedule.
We can also contract with you for biomarker development using our proprietary technology (M-TEST) for genome-wide discovery of abnormal methylation in cell-free DNA (liquid biopsy).
We look for informative features in tissues and in cell-free DNA from blood or other biological fluids, combine these features into a composite biomarker using a dedicated software algorithm. We then compute sensitivity and specificity of this biomarker and validate its performance.
Developed biomarker is the final product of our discovery, development, and validation services for blood-based biomarkers. We will help you get there quickly and smoothly. That’s how we ensure your success.
informative features combined into a composite biomarker provide the comprehensive info required for precise diagnosis, prediction of response, or to determine the natural course of the disease. When several features agree, the biomarker strategies provide multiple layers of confirmation for the right diagnosis or prediction of response.
Disease and its response to treatment are defined by gene expression, so the best biomarkers in medicine are those that reflect gene expression.
Epigenetic features (DNA methylation) are linked to gene expression and can be tested in biological fluids, for example in blood (aka liquid biopsy).
At this time DNA methylation is the most powerful tool for biomarker development in blood.
Blood-based biomarkers in cancer are key for diagnosis and prediction of response—that’s why when it comes to project selection, we’re choosy. We want to give each of you the time and guidance you deserve to ensure successful discovery of biomarkers of your choice. If you’re seeking the right partner or a special skillset, call us today. Together we’ll create and refine your plan for success. We didn’t get there alone. And neither will you.